Selected common diagnostic problems in urologic pathology: Perspectives from a large consult service in genitourinary pathology

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 4, 2012, Pages 360-371

  Brimo, Fadi ^a   Epstein, Jonathan I ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ACINAR CELL CARCINOMA; ARTICLE; ATROPHY; BLADDER; CARCINOMA IN SITU; DIFFERENTIAL DIAGNOSIS; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; ONCOCYTOMA; PATHOLOGY; PROSTATE; PROSTATE TUMOR; URINARY TRACT CANCER; UROGENITAL TRACT TUMOR; UROTHELIUM;

ADENOMA, OXYPHILIC; ATROPHY; CARCINOMA IN SITU; CARCINOMA, ACINAR CELL; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; KIDNEY NEOPLASMS; MALE; PROSTATE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; UROGENITAL NEOPLASMS; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84860012574     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0187-RA     Document Type: Article

References (26)

1. Oppenheimer JR, Wills ML, Epstein JI. Partial atrophy in prostate needle cores: another diagnostic pitfall for the surgical pathologist. Am J Surg Pathol. 1998;22(4):440-445. (Pubitemid 28164550)
2. De Marzo AM, Platz EA, Epstein JI, et al. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol. 2006;30(10):1281-1291. (Pubitemid 44454708)
3. Beach R, Gown AM, De Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26(12):1588-1596. (Pubitemid 35387221)
4. Farinola MA, Epstein JI. Utility of immunohistochemistry for a-methylacyl- CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. Hum Pathol. 2004;35(10):1272-1278. (Pubitemid 39361652)
5. Cina SJ, Epstein JI. Adenocarcinoma of the prostate with atrophic features. Am J Surg Pathol. 1997;21(3):289-295. (Pubitemid 27120197)
6. Demirovic A, Cesarec S, Spajic B, et al. Can renal oncocytoma be distinguished from chromophobe renal cell carcinoma by the presence of fibrous capsule? Virchows Arch. 2010;456(1):85-89.
7. Amin MB, Crotty TB, Tickoo SK, Farrow GM. Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases. Am J Surg Pathol. 1997;21(1):1-12. (Pubitemid 27026600)
8. Trpkov K, Yilmaz A, Uzer D, et al. Renal oncocytoma revisited: a clinicopathological study of 109 cases with emphasis on problematic diagnostic features. Histopathology. 2010;57(6):893-906.
9. Hes O, Michal M, Sima R, et al. Renal oncocytoma with and without intravascular extension into the branches of renal vein have the same morphological, immunohistochemical and genetic features. Virchows Arch. 2008;452(3):193-200.
10. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135(1):92-109.
11. Yusenko MV, Zubakov D, Kovacs G. Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by Affymetrix GeneChip using pooled and individual tumours. Int J Biol Sci. 2009;5(6):517-527.
12. Kauffman EC, Barocas DA, Chen YT, Yang XJ, Scherr DS, Tu JJ. Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes. J Urol. 2009;181(5):2305-2311.
13. Tickoo SK, Reuter VE, Amin MB, et al. Renal oncocytosis: a morphologic study of fourteen cases. Am J Surg Pathol. 1999;23(9):1094-1101. (Pubitemid 29409772)
14. Adley BP, Smith ND, Nayar R, Yang XJ. Birt-Hogg-Dube syndrome: clinicopathologic findings and genetic alterations. Arch Pathol Lab Med. 2006; 130(12):1865-1870. (Pubitemid 44906968)
15. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg- Dube syndrome. Am J Surg Pathol. 2002;26(12):1542-1552. (Pubitemid 35387218)
16. Cannata-Ortiz P, Rodriguez BW, Bratlavsky G, Linehan WM, Merino MJ. Hybrid tumors: all you need to know and more [abstract 766]. Mod Pathol. 2011; 24(suppl 1):182A.
17. Eisengart LJ, Tretiakova M, Rohan SM, et al. Hybrid oncocytic tumors of the kidney in patients with Birt-Hogg-Dube (BHD) syndrome [abstract 832]. Mod Pathol. 2010; 23(suppl 1):188A.
18. Petersson F, Gatalica Z, Grossmann P, et al. Sporadic hybrid oncocytic/ chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases. Virchows Arch. 456(4):355-365.
19. Waldert M, Klatte T, Haitel A, et al. Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol. 57(4):661-665.
20. Argüelles Salido E, Marcilla Plaza D, Medina López R, Congregado Ruiz B, Campoy Martinez P, Cayuela Dominguez A. Renal oncocytoma: review of our 22 patients [in Spanish]. Actas Urol Esp. 2006;30(6):583-590. (Pubitemid 44911193)
21. Epstein JI, Amin MB, Reuter VR, Mostofi FK; Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22(12):1435-1448. (Pubitemid 28550639)
22. McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol. 2001;25(3):356-362. (Pubitemid 32174205)
23. Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol. 1996;78(6):870-875. (Pubitemid 27407788)
24. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 1993;85(1):53-59. (Pubitemid 23023225)
25. Gilbert CM, Parwani A. The use of multispectral imaging to distinguish reactive urothelium from neoplastic urothelium. J Pathol Inform. 2010;1:23.
26. Edgecombe A, Belanger EC, Djordjevic B, Nguyen BN, Mai KT. Cytokeratin 5/6 distinguishes reactive urothelial atypia from carcinoma in situ and noninvasive urothelial carcinoma [abstract 798]. Mod Pathol. 2011;24 (suppl 1):190A.